ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Aeromonas dhakensis as an emerging invasive pathogen: a case series highlighting distinct carbapenem resistance and diagnostic challenge.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Species distribution, antimicrobial resistance, and putative virulence factor profiles ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAeromonas dhakensis is an emerging and potentially more virulent species within the Aeromonas genus, frequently misidentified in routine laboratories, leading to underrecognition and suboptimal management.
objectivesTo describe the clinical spectrum, laboratory characteristics, and antimicrobial susceptibility patterns of A. dhakensis isolated from clinically significant specimens in a tertiary-care setting.
methodsA retrospective case series was conducted at a tertiary-care teaching hospital during November-December 2025. Clinical and microbiological records of patients with A. dhakensis isolated from clinically relevant specimens were reviewed. Species identification was performed using MALDI-TOF MS with updated databases, and antimicrobial susceptibility testing was interpreted according to CLSI guidelines.
resultsFour cases of clinically significant A. dhakensis infection were identified (median age 43 years), involving pleural fluid, pus aspirate, endotracheal aspirate, and urine. Clinical presentations included hydropneumothorax, breast abscess, neurosurgical complications, and urinary tract infection. Two patients required ICU care and mechanical ventilation. Laboratory findings showed mild anemia and leukocytosis in select cases. All isolates demonstrated uniform resistance to carbapenems and piperacillin-tazobactam, while retaining susceptibility to fluoroquinolones, aminoglycosides, third- and fourth-generation cephalosporins, aztreonam, trimethoprim-sulfamethoxazole, and doxycycline. All patients improved with appropriate therapy and survived to discharge.
conclusionA. dhakensis is an emerging invasive pathogen with a characteristic resistance profile marked by intrinsic carbapenem resistance. Accurate species-level identification using MALDI-TOF MS and susceptibility-guided therapy are essential. This study provides region-specific evidence highlighting the need for increased clinical awareness, diagnostic stewardship, and surveillance.
Indexed as
Identifiers
42350858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.